Oraya Therapeutics And OnCore Manufacturing Complete Production Of Innovative Device For Wet Age-Related Macular Degeneration

Published: Nov 12, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif. & FREMONT, Calif.--(BUSINESS WIRE)--Oraya® Therapeutics, Inc. and OnCore Manufacturing LLC announced today the production of the first commercial unit in the United States of the IRay® Radiotherapy System for the treatment of wet age-related macular degeneration (AMD), the leading cause of permanent vision loss in the industrialized world. IRay, the medical device at the core of Oraya Therapy, is CE marked and is currently available in the United Kingdom and Switzerland. The first commercial production comes as Oraya and OnCore have signed a long-term contract to facilitate Oraya’s continued expansion in Europe.

Help employers find you! Check out all the jobs and post your resume.

Back to news